Society for Neuro-Oncology Annual Meeting 2019
Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM: Half-Way Report
Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM: Half-Way Report
Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor growth upon bevacizumab-induced hypoxia, in vivo
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the adjuvant or recurrent setting
Phase 2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma
Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of diffuse intrinsic pontine glioma (DIPG)
Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve recurrent glioblastoma
Phase 1/2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma
Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of diffuse intrinsic pontine glioma (DIPG)
VAL-083 inhibits proliferation of a panel of eight glioblastoma stem cells: Downregulation of BRD4 as a novel anti-neoplastic mechanism
Dianhydrogalactitol (VAL-083) has a distinct mechanism of action that suggests combination with PARP inhibitors as an effective therapeutic strategy